A Phase 2/3 Multicenter, Dose-response Study to Assess Efficacy and Safety of ZS (Sodium Zirconium Cyclosilicate), in Japanese Patients With Hyperkalemia
Phase of Trial: Phase II/III
Latest Information Update: 21 May 2019
Price : $35 *
At a glance
- Drugs Zirconium silicate (Primary)
- Indications Hyperkalaemia
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 05 Mar 2018 Status changed from active, no longer recruiting to completed.
- 19 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 19 Feb 2018 Planned End Date changed from 14 Feb 2018 to 1 Mar 2018.